Qilu Pharmaceutical’s Iruplinalkib Receives NMPA Approval for ALK+ NSCLC Treatment
China-based Qilu Pharmaceutical has announced that its Category 1 chemical drug, iruplinalkib, an ALK inhibitor,...
Fineline Cube
Jiangsu Hengrui’s Oteseconazole (SHR8008) Approved by NMPA for Severe Vulvovaginal Candidiasis
The National Medical Products Administration (NMPA) has granted approval to China-based Jiangsu Hengrui Pharmaceuticals Co.,...
WestGene Biopharma Secures $42 Million in Funding to Advance mRNA Therapeutics
Chengdu-based mRNA specialist WestGene Biopharma has reportedly raised USD 42 million via a funding round,...
Pfizer Partners with CSPC Pharmaceutical to Localize Paxlovid in China
US pharmaceutical major Pfizer (NYSE: PFE) has entered into a partnership with China-based CSPC Pharmaceutical...
EOC Pharma’s Lusutrombopag Receives NMPA Approval for Chronic Liver Disease Treatment
China-based EOC Pharma Group has announced that its drug, lusutrombopag, has received marketing approval from...
Changchun BCHT Biotechnology to Acquire Full Stake in mRNA R&D Firm Transcend Biomedical
China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced its intention to invest in...
Jiangsu Simcere’s Edaravone, Borneol Sublingual Tablets for AIS Accepted by NMPA for Review
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced that the National Medical Products Administration...
Shanghai Junshi Biosciences Gets FDA Approval for Phase III Study of Tifcemalimab in Small-Cell Lung Cancer
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877) has announced receiving approval from the US Food...
Worg Pharmaceuticals Secures RMB 1.1 Billion in Series C Financing for Global Expansion
Worg Pharmaceuticals, a Hangzhou-based developer of allergy drugs, has reportedly raised RMB 1.1 billion (USD...
AIM Vaccine Receives NMPA Approval for mRNA Vaccine Clinical Study Targeting COVID-19 Variants
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving approval from the National Medical...
Sichuan Kelun-Biotech Biopharmaceutical Prices IPO at HKD 60.6 to 72.8 per Share
Sichuan Kelun Pharmaceutical Co., Ltd’s (SHE: 002422) innovative drug development subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co.,...
Shandong Buchang Pharmaceuticals’ BC001 Gets Clinical Trial Approval for Solid Tumors
Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858), a China-based pharmaceutical company, has announced receiving clinical...
Beijing Tiantan Biological Completes Phase I Study for Recombinant Coagulation Factor VIIa
China-based Beijing Tiantan Biological Products Co., Ltd (SHA: 600161) has announced the conclusion of a...
Shanghai’s SMPA Notification: Non-Winning Bids in VBP Round 8 Can Avoid “Higher Price” Label
Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has released a notification concerning the 8th round of...
US FDA Issues Warning Letter to Chengdu KeCheng Fine Chemicals Over Communication Failures
The US FDA’s Center for Drug Evaluation (CDE) issued a warning letter to China-based Chengdu...
Grand Pharmaceutical Initiates Phase I Study for TLX250-CDx in Renal Mass Imaging
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the first patient dosing in the...
Teva Pharmaceutical’s Copaxone Approved by NMPA for Multiple Sclerosis Treatment in China
The National Medical Products Administration (NMPA) website has indicated that Israel-based Teva Pharmaceutical Industries’ (NYSE:...
Fosun Pharmaceutical’s Sisram Opens Wellness Center in Chicago for Beauty and Health
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the establishment of...
Sanyou Biopharmaceuticals and Huadong Medicine Expand Partnership on Macromolecule Therapeutics
China-based Sanyou Biopharmaceuticals Co., Ltd has announced a licensing deal with compatriot firm Huadong Medicine...
Daewoong Pharmaceutical Files NDA in China for Potassium-Competitive Acid Blocker Fexuclu
South Korea-based Daewoong Pharmaceutical (KRX: 069620) has revealed that a new drug application (NDA) has...